The AMPK-SIRT1 Axis: Redefining Type 2 Diabetes Mellitus Management DOI
Mighty Kgalalelo Kemelo,

Phillip Moseki

Опубликована: Янв. 1, 2024

Язык: Английский

Evaluation of clinical benefits and economic value of weight loss in a Swedish population using a simulation model DOI Creative Commons
Marije Galavazi, Ville Wallenius, Volker Schnecke

и другие.

Obesity, Год журнала: 2025, Номер unknown

Опубликована: Март 12, 2025

Abstract Objective The objective of this study was to estimate the 10‐year clinical benefits and economic value weight loss in a Swedish population with obesity using weight‐loss simulation model. Methods Data on prevalence costs associated obesity‐related complications (ORCs) were applied within an adapted model evaluate for 2023 over 10 years. incidence ORCs treatment random cohort 10,000 individuals estimated stable scenario four (5%–20%) scenarios. Results included 887,272 aged 20 60 Hypertension (24.1%), asthma (20.9%), dyslipidemia (18.3%), type 2 diabetes (10.6%) highly prevalent. For individuals, 5% 20% prevent years, leading annual savings between 9.0 million krona (SEK)/€0.8 (5% loss) 30.0 SEK/€2.6 (20%) by 2033. Conclusions Annual Sweden will double would be significant because reductions ORCs. Therefore, there is urgent need effectively treat morbidity.

Язык: Английский

Процитировано

0

Evaluating the Performance and Safety of Large Language Models in Generating Type 2 Diabetes Mellitus Management Plans: A Comparative Study With Physicians Using Real Patient Records DOI Open Access
Agnibho Mondal, Arindam Naskar,

Bhaskar Roy Choudhury

и другие.

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Background The integration of large language models (LLMs) such as GPT-4 into healthcare presents potential benefits and challenges. While LLMs show promise in applications ranging from scientific writing to personalized medicine, their practical utility safety clinical settings remain under scrutiny. Concerns about accuracy, ethical considerations, bias necessitate rigorous evaluation these technologies against established medical standards. Methods This study involved a comparative analysis using anonymized patient records setting the state West Bengal, India. Management plans for 50 patients with type 2 diabetes mellitus were generated by three physicians, who blinded each other's responses. These evaluated reference management plan based on American Diabetes Society guidelines. Completeness, necessity, dosage accuracy quantified Prescribing Error Score was devised assess quality plans. also assessed. Results indicated that physicians' had fewer missing medications compared those (p=0.008). However, GPT-4-generated included unnecessary (p=0.003). No significant difference observed drug dosages (p=0.975). overall error scores comparable between physicians (p=0.301). Safety issues noted 16% GPT-4, highlighting risks associated AI-generated Conclusion demonstrates while can effectively reduce prescriptions, it does not yet match performance terms completeness. findings support use supplementary tools healthcare, need enhanced algorithms continuous human oversight ensure efficacy artificial intelligence settings.

Язык: Английский

Процитировано

0

Artificial intelligence in diabetes management: transformative potential, challenges, and opportunities in healthcare DOI

Arnabjyoti Deva Sarma,

Moitrayee Devi

HORMONES, Год журнала: 2025, Номер unknown

Опубликована: Март 21, 2025

Язык: Английский

Процитировано

0

Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication DOI Creative Commons
Thim Prætorius, Anne Sofie Baymler Lundberg, Eskild Klausen Fredslund

и другие.

npj Digital Medicine, Год журнала: 2025, Номер 8(1)

Опубликована: Март 28, 2025

Although promising, the clinical impact of video conferencing between primary and secondary care specialists lacks trial evidence. We conducted a two-arm RCT (clinicaltrials.gov: NCT05268081) to evaluate whether four conferences over 12 months endocrinologists general practitioners improved medication for people with type 2 diabetes (T2D). Twenty-seven 100 practices in Aarhus, Denmark were matched randomized. Primary outcomes: proportion T2D 1) ischemic heart disease treated glucagon-like peptide 1 receptor agonist (GLP1-RA) and/or sodium glucose cotransporter inhibitor (SGLT2I), 2) micro/macro-albuminuria angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2), 3) low-density lipoprotein >2.5 mmol/L statins. Results showed 17.6% difference [95% CI 4.6%; 30.7%] GLP1-RA/SGLT2I prescriptions minimal differences ACE/AT2 (−1.1% −2.8%; 0.6%]) statins (0.0% −3.5%; 3.6%]), attributed ceiling effect. Video can help bridge treatment gaps, particularly recently updated guidelines.

Язык: Английский

Процитировано

0

Prophylactic vaccination strategies for adult patients with diabetes: a narrative review of safety profiles and clinical effectiveness DOI Creative Commons
Olivia Cicilia Walewangko,

Jonathan Suciono Purnomo,

Pranasha Amabella Jo

и другие.

Clinical and Experimental Vaccine Research, Год журнала: 2025, Номер 14

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery DOI Creative Commons
Shounak Sarkhel, Sohul Shuvo,

Md Ahesan Ansari

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(12), С. 1572 - 1572

Опубликована: Дек. 9, 2024

Diabetes is a widespread metabolic illness. Mismanagement of diabetes can lead to severe complications that tremendously impact patients’ quality life. The assimilation nanotechnology in care holds the potential revolutionize treatment paradigms, improve patient outcomes, and reduce economic burden associated with this pervasive disease. This manuscript explores multifaceted utilization nanomaterials care, emphasizing unique features nano-based medication delivery methods smart drug mechanisms. Additionally, paper talks about research on nanocarrier-integrated oral, transdermal, inhalable insulin delivery; dendrimer- nanocarrier-coupled antisense oligonucleotide-driven gene therapy; implementation gold nanoparticles quantum dots for glucose surveillance; nucleic acid therapies. There are certain restrictions when using commonly available handle diabetes. In order increase efficacy safety, rapidly developing science also being explored employed medical biology. Nanomaterials like liposomes, dendrimers, niosomes, polymeric metallic nanocarriers, solid lipid among nanocarriers have been developed better various oral hypoglycemic agents comparison conventional These provide great control over elevated blood levels, making them one most intriguing promising technologies today. Furthermore, adding additional ligands allows more focused distribution while protecting encapsulated drugs.

Язык: Английский

Процитировано

2

Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels DOI Creative Commons
Brisnovali Niki Fanouriou,

Isabelle Franco,

Amira Abdelgawwad

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Апрель 22, 2024

Abstract Despite recent therapeutic advances, achieving optimal glycaemic control remains a challenge in managing Type 2 Diabetes (T2D). Sodium-glucose co-transporter type (SGLT2) inhibitors have emerged as effective treatments by promoting urinary glucose excretion. However, the full scope of their mechanisms extends beyond control. At present, immunometabolic effects remain elusive. To investigate SGLT2 inhibition or deletion, we compared metabolic and immune phenotype between high fat diet-fed control, chronically dapagliflozin-treated mice total-body SGLT2/ Slc5a2 knockout mice. null exhibited superior tolerance insulin sensitivity to mice, independent glycosuria body weight. Moreover, demonstrated physiological regulation corticosterone secretion, with lowered morning levels Systemic cytokine profiling also unveiled significant alterations inflammatory mediators, particularly interleukin 6 (IL-6). Furthermore, unbiased proteomic analysis downregulation acute-phase proteins upregulation glutathione-related proteins, suggesting role modulation antioxidant responses. Conversely, IL-6 increased expression kidney HK2 cells for cytokines hyperglycemia. Collectively, our study elucidates potential interplay activity, modulation, homeostasis. Graphical Article Highlights The immunity elusive, despite extensive research inhibitors. We sought discern deletion on profiles high-fat-fed focussing alterations. exhibit enhanced sensitivity, alongside physiologically regulated cytokines, identified changes protein suggestive modulation. Our findings emphasize responses mediated activity.

Язык: Английский

Процитировано

1

Lack of glycemic control in type two diabetes mellitus patients is associated with reduced serum epidermal growth factor level and increased insulin resistance DOI Open Access
Ahmed Al‐Dwairi, Mahmoud A. Alfaqih, Rami Saadeh

и другие.

Biomedical Reports, Год журнала: 2024, Номер 22(1)

Опубликована: Окт. 29, 2024

The prevalence of type 2 diabetes mellitus (T2DM) is steadily increasing worldwide in an alarming fashion. Importantly, poor glycemic control associated with development various health sequalae's due to glucolipotoxicity, oxidative stress and increased inflammatory cytokines. aim the present study was examine effect on relative abundance markers patients controlled uncontrolled T2DM, test their association status diabetic Jordan. An observational cross-sectional design used. Patients T2DM [glycated hemoglobin (HbA

Язык: Английский

Процитировано

1

Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology DOI Creative Commons
Е. Л. Насонов, Т. С. Паневин, Е. А. Трошина

и другие.

Rheumatology Science and Practice, Год журнала: 2024, Номер 62(2), С. 135 - 144

Опубликована: Апрель 28, 2024

Glucagon-like peptide-1 receptor agonists (ArGLP-1) are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range immunoinflammatory diseases suggest important pleiotropic mechanisms action these drugs, primarily related to suppression inflammation. The article presents new data indicating prospects use ArGLP-1 rheumatic diseases, which dictates need clinical studies. GLP-1 immune-mediated

Язык: Английский

Процитировано

0

Evaluating the Effectiveness and Safety of Large Language Model in Generating Type 2 Diabetes Mellitus Management Plans: A Comparative Study with Medical Experts Based on Real Patient Records DOI Open Access
Agnibho Mondal, Arindam Naskar,

Bhaskar Roy Choudhury

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Май 22, 2024

Abstract Background The integration of large language models (LLMs) such as GPT-4 into healthcare presents potential benefits and challenges. While LLMs have shown promise in applications ranging from scientific writing to personalized medicine, their practical utility safety clinical settings remain under scrutiny. Concerns about accuracy, ethical considerations bias necessitate rigorous evaluation these technologies against established medical standards. Objective To compare the completeness, necessity, dosage accuracy overall type 2 diabetes management plans created by with those devised experts. Methods This study involved a comparative analysis using anonymized patient records setting West Bengal, India. Management for 50 Type patients were generated three blinded These evaluated reference plan based on American Diabetes Society guidelines. Completeness, necessity quantified an error score was assess quality plans. also assessed. Results indicated that experts’ had fewer missing medications compared (p=0.008). However, included unnecessary (p=0.003). No significant difference observed drug dosages (p=0.975). scores comparable between human experts (p=0.301). Safety issues noted 16% GPT-4, highlighting risks associated AI-generated Conclusion demonstrates while can effectively reduce prescriptions, it does not yet match performance terms completeness safety. findings support use supplementary tools healthcare, underscoring need enhanced algorithms continuous oversight ensure efficacy AI settings. Further research is necessary improve complex environments.

Язык: Английский

Процитировано

0